^
    Apply
    A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation (NCT05485974)
    Phase 1
    HUYABIO International, LLC.
    Recruiting
    Last update posted :
    09/13/2023
    Initiation :
    08/01/2022
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    sosimerasib (HBI-2438)